Materials of the Fifth International Conference on Science and Business
Science and Training for Biosafety
208
Virulent bacteriophages are the main subject of phage-therapy preparations, and the
formation of pseudolysogens may be rather significant for treatment. Owing to formation of
pseudolysogenic clones, virulent bacteriophages are able to transduce different genes (13-17).
These may be the genes responsible for pathogenesis as well as the genes of resistance to
antibiotics. For example, under bacteriophage treatment for diarrheas, a virulent bacteriophage
capable of transduction can provide the transfer of the genes of antibiotic resistance between
pathogenic bacteria and the normal intestinal flora. These may be virulent Shigella and non-
virulent Escherichia strains. Later on, antibiotic-resistant non-pathogenic bacteria may provide
distribution of the genes of antibiotic resistance due to horizontal transfer by way of the same
transduction or conjugation. Introduction of new virulent bacteriophages into practice requires
their testing for the ability to transduce genetic material: both chromosomal and plasmid
markers.
Theoretically, only bacteriophages incapable of transduction can be used. At the same
time, it seems insufficient to test bacteriophages only under conditions of microbiological
laboratory. It is necessary not only to test them in pure culture but also to perform experiments
with laboratory animals and experimental infection in vivo (18).
The work was supported by RFBR grants №07-04-01563а, №08-04-10149-к, №08-04-
99111офи_р.
References
1. Gamaleya N.F., Russ. Arch. Pathol. Clin. Med. Bacteriol. 1898, 6:607-613.
2. Twort F.W. Lancet 1915 ii:1241-1243.
3. d’Herelle F. C. R. Acad. Sci. Paris. 1917. 165:373–375.
4. d’Herelle, F. in The Bacteriophage: Its Role in Immunity, (Williams & Wilkins,
Baltimore) (1922). 5.Summers W. C. Annu. Rev. Microbiol. 2001. 55:437–451.
6. Inal J.M. Arch Immunol Ther Exp (Warsz). 2003 51(4):237-44.
7. Barrow P. A. J. Chem. Technol. Biotechnol. 2001. 76:677–682.
8. Barrow P.A., Soothill J.S. Trends in Microbiology. 1997. №5: 268-271.
9. Follet G. Antibiotic Resistance. In The EU—Science, Politics, And Policy //
AgBioForum, 2000, Vol. 3, № 2-3, pp. 148-155.
10. Sulakvelidze, A. & Kutter, E. (2005). Bacteriophage therapy in humans. In
Bacteriophages – Biology and Applications, pp. 381–436. Edited by E. Kutter & A.
Sulakvelidze. Boca Raton, FL: CRC Press.
11. Sulakvelidze, A., Alavidze, Z. & Morris, J. G., Jr (2001). Antimicrob Agents
Chemother 45, 649–659.
12. Summers, W. C. (1999). Fe´lix d’He´relle and the Origins of Molecular Biology.
New Haven, CT: Yale University Press.
13. Fraser D.K. Virology. 1957. V. 3., № 3.pр. 527–553.
14. Tanyashin V.I., Boronin A.M. Doklady Biochemistry. 1998. V.363. N6. pp. 849-
852.
15. Tanyashin V.I., Zimin A.A., Boronin A.M. Microbiologia (in Russian.). 2003, V
72, 6, pp. 785 – 791.
16. Tanyashin V.I., Zimin A.A., Shlyapnikov M.G., Boronin A.M. Genetika (in
Russian.), 2003, V 39, №7, pp. 1-13.
17. Zimin A. A., Vasilyeva E. A., Suzina N. E., Ivanov A. M., Boronin A. M. Abstracts
of the Fourth International Conference on “Science and Business” October 15 – 18. 2007,
Pushchino, pp. 266 - 269..
18. Zimin A. A., Vasilyeva E. L., Murashev A. N. Abstracts of the Fourth International
Conference on “Science and Business” October 15 – 18. 2007, Pushchino, pp. 262 - 265.